title: Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.
abstract: Everolimus is a potent, oral inhibitor of the mammalian target of rapamycin (mTOR) that has been investigated in multiple clinical development programs since 1996. A unique collaboration between academic and pharmaceutical experts fostered research that progressed rapidly, with simultaneous indication findings across numerous tumor types. Initially developed for the prophylaxis of organ transplant rejection, everolimus has demonstrated efficacy and safety for the treatment of patients with various types of cancer (renal cell carcinoma, neuroendocrine tumors of pancreatic origin, and breast cancer) and for adult and pediatric patients with tuberous sclerosis complex. The FDA approval of everolimus for these diseases has addressed several unmet medical needs and is widely accepted by the medical community where treatment options may be limited. An extensive clinical development program is ongoing to establish the role of everolimus as monotherapy, or in combination with other agents, in the treatment of a broad spectrum of malignancies.
authors: Novartis Pharmaceuticals Corporation, Florham Park, New Jersey 07932, USA. david.lebwohl@novartis.com
authors: David
authors: D
authors: Lebwohl
authors: Ozlem
authors: O
authors: Anak
authors: Tarek
authors: T
authors: Sahmoud
authors: Judith
authors: J
authors: Klimovsky
authors: Ingrid
authors: I
authors: Elmroth
authors: Tomas
authors: T
authors: Haas
authors: Joseph
authors: J
authors: Posluszny
authors: Stephen
authors: S
authors: Saletan
authors: William
authors: W
authors: Berg
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000276:immunology; D002986:Clinical Trials as Topic / Q000379:methods; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000737:chemistry; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000276:immunology; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000276:immunology; D014402:Tuberous Sclerosis / Q000188:drug therapy / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus
keywords: cancer; everolimus; mTOR inhibitor; tuberous sclerosis complex